Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

5.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.1K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

617
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
617
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

51
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
51
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

701
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
701
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

219
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

39
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
39

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of Factors Determining the Stiffness and Elasticity of Scars in Women After Cesarean Section-A Pilot Study.

Journal of clinical medicine·2026
Same author

The Impact of Maternal BMI on the Efficacy and Safety of Oral Misoprostol for Labor Induction.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Cervical Glycosaminoglycans and Extracellular Matrix Remodeling: New Insights and the Therapeutic Promise of Tafoxiparin.

Cells·2025
Same author

Lactoferrin and SIgA Concentrations in Human Milk of SARS-CoV-Infected Mothers-Polish Cohort Study.

Nutrients·2025
Same author

Human Milk Microbiome from Polish Women Giving Birth via Vaginal Delivery-Pilot Study.

Biology·2025
Same author

Enhanced Non-Invasive Diagnosis of Female Urinary Incontinence Using Static and Functional Transperineal Ultrasonography.

Diagnostics (Basel, Switzerland)·2024

Related Experiment Video

Updated: Aug 24, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

901

Decrease in Nitric Oxide Production as a Key Mediator in the Pathogenesis of Preeclampsia and a Potential Therapeutic

Maciej W Socha1,2, Martyna Stankiewicz1, Krzysztof Żołnieżewicz1

  • 1Department of Perinatology, Gynecology and Gynecologic Oncology, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Łukasiewicza 1, 85-821 Bydgoszcz, Poland.

Biomedicines
|October 27, 2022
PubMed
Summary

Nitric oxide (NO) metabolism is altered in pre-eclampsia (PE), a condition causing pregnancy-induced hypertension. Lower levels of NO metabolites (NOx) in PE patients suggest a role in endothelial dysfunction and potential therapeutic targets.

Keywords:
NOgestational hypertensionhypertensive pregnancynitric oxidepreeclampsiapregnancy complications

More Related Videos

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

16.0K
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

4.3K

Related Experiment Videos

Last Updated: Aug 24, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

901
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

16.0K
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

4.3K

Area of Science:

  • Obstetrics and Gynecology
  • Cardiovascular Research
  • Biochemistry

Background:

  • Gestational hypertension (GH) affects 6-10% of pregnancies, with pre-eclampsia (PE) as a leading cause of maternal mortality.
  • Pre-eclampsia significantly contributes to global maternal morbidity and mortality, necessitating research into its underlying mechanisms.

Purpose of the Study:

  • To investigate alterations in nitric oxide (NO) metabolism during the progression of pre-eclampsia.
  • To determine if NO metabolite levels differ between pregnant women with and without pre-eclampsia.

Main Methods:

  • Measured stable nitric oxide metabolites (nitrite and nitrate, NOx) in 58 patients with early pre-eclampsia and 42 healthy pregnant controls.
  • Compared NOx concentrations between the pre-eclampsia group and the healthy control group.

Main Results:

  • Significantly lower NOx concentrations were observed in the pre-eclampsia group (mean 5.33 μmol/L) compared to the healthy control group (mean 27.64 μmol/L).
  • The reduction in NO metabolites suggests a link to systemic endothelial dysfunction in pre-eclampsia.

Conclusions:

  • Impaired NO metabolism is implicated in the pathogenesis of pre-eclampsia.
  • Nitric oxide metabolism represents a potential therapeutic target for managing pre-eclampsia.